150.00p+1.00 (+0.67%)25 May 2022, 18:54
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Novacyt S.A. Fundamentals

Company NameNovacyt S.A.Last Updated2022-05-25
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue70.626 mMarket Cap£105.94 m
PE Ratio1.19Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£1.94EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0114Debt Equity Ratio0.0123
Asset Equity Ratio1.3149Cash Equity Ratio0.5573
Quick Ratio3.1956Current Ratio4.46
Price To Book Value0.7421ROCE0

Novacyt S.A. Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Novacyt S.A. Company Financials

Tangible Assets£3.90 m£2.97 m
Intangible Assets£22.13 m£17.27 m
Total Fixed Assets£29.29 m£20.62 m
Stocks£29.89 m£2.08 m
Debtors£79.25 m£1.52 m
Cash & Equivalents£91.77 m£1.55 m
Other Assets£3.24 m£372,000.00
Total Assets£234.28 m£26.53 m
Creditors within 1 year£74.14 m£5.84 m
Creditors after 1 year£9.42 m£8.22 m
Other Liabilities00
Total Liabilities£83.57 m£14.06 m
Net assets£150.71 m£12.46 m
Called up share capital£4.05 m£3.31 m
Share Premium£50.67 m£47.00 m
Profit / Loss£165.17 m-£3.43 m
Other Equity£150.71 m£12.46 m
Preference & Minorities00
Total Capital Employed£150.71 m£12.46 m
Debt Ratio£0.01£0.39
Assets / Equity1.31491.3149
Cash / Equity0.55730.5573
Cash Flow20202019
Cash from operating activities£102.98 m-£941,000.00
Cashflow before financing£97.94 m£1.55 m
Increase in Cash£89.97 m£507,000.00
Turnover£277.20 m£11.47 m
Cost of sales£66.08 m£4.42 m
Gross Profit£211.13 m£7.04 m
Operating Profit£167.44 m-£1.56 m
Pre-Tax profit£165.17 m-£3.43 m

Novacyt S.A. Company Background

ActivitiesNovacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. Its diagnostic products are used in LBC, oncology, microbiology, hematology, and serology testing. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: Lab21 Product segment is a developer, manufacturer, and distributor of a large range of protein-based infectious disease IVD products; IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.
Latest Interim Date27 Sep 2021
Latest Fiscal Year End Date28 Apr 2022

Novacyt S.A. Directors

2021-07-29Mr. Graham D. MullisExecutive Director,Chief Executive Officer
2021-06-29Dr. Andrew John William HeathNon-Executive Director
2021-06-29Dr. Edwin SnapeNon-Executive Director
2021-06-29Mr. Anthony Stephen DyerExecutive Director,Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.
2021-06-29Mr. James Christopher WakefieldNon-Executive Director,Chairman
2021-06-29Mr. Jean-Pierre Jacques CrinelliNon-Executive Director

Novacyt S.A. Contact Details

Company NameNovacyt SA
Address13, Avenue Morane Saulnier, Velizy-Villacoublay, 78140
Telephone+33 139465104

Novacyt S.A. Advisors